Jennerex appoints Dr James Burke VP of clinical research
This article was originally published in Scrip
Jennerex, a San Francisco-based cancer biotherapeutics company, has appointed Dr James Burke to the newly-created position of vice-president of clinical research; he will be responsible for global clinical research activities related to Jennerex' pipeline. Dr Burke, who has 20 years' experience in the clinical science of genetic and immunotherapy, has been working with Jennerex in an advisory capacity as a clinical advisor for more than a year.
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.